Home > Oncology > ASCO 2020 > Gastrointestinal Cancer > Pembrolizumab as first-line in MSI-H mCRC

Pembrolizumab as first-line in MSI-H mCRC

Prof. Thierry André, St Antoine Hospital, France
ASCO 2020
Phase 3, KEYNOTE-177
Featured video: Phase III Keynote-177 trial comparing pembrolizumab to standard therapy as first-line treatment for select patients with advanced colorectal cancer.   The first phase 3 study of pembrolizumab versus standard-of-care (i.e. chemotherapy + bevacizumab or cetuximab) demonstrated superiority for first-line pembrolizumab in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC), reported Prof. Thierry André (St Antoine Hospital, France) [1]. About 5% of all mCRC is characterised by MSI-H, often linked with germline mutations in Lynch syndrome. Mismatch repair status and MSI-H predict clinical benefit of immune checkpoint blockade with pembrolizumab as first-line therapy for MSI-H mCRC and has been FDA approved for adults and children with metastatic tumours with MSI, regardless of the tumour type. Previously,

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on